Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
| ▸ | STAT3 | P40763 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10409481 | 0.75 | — | — | |
| SCHEMBL1450383 | 0.75 | ANPEP (0.35) | — | |
| SCHEMBL1450861 | 0.75 | — | — | |
| SCHEMBL1451246 | 0.75 | ANPEP (0.35) | — | |
| SCHEMBL1450376 | 0.75 | ANPEP (0.35) | — | |
| SCHEMBL11823733 | 0.73 | — | — | |
| SCHEMBL1450540 | 0.73 | — | — | |
| SCHEMBL315647 | 0.71 | BRD4 (0.54) | BRD4CREBBPACHE | |
| SCHEMBL3797734 | 0.71 | BRD4 (0.35) | BRD4CREBBP | |
| SCHEMBL9146155 | 0.69 | BRD4 (0.31) | BRD4CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11931412-B2 | JAK1 inhibitors and uses thereof | WASHINGTON UNIVERSITY (US) | 2024-03-19 | — | — | US | disclosed |
| US-20210338812-A1 | JAK1 INHIBITORS AND USES THEREOF | WASHINGTON UNIVERSITY (US) | 2021-11-04 | — | — | US | disclosed |
| US-10973913-B2 | JAK inhibitors and uses thereof | WASHINGTON UNIVERSITY (US) | 2021-04-13 | — | — | US | disclosed |
| US-20200282051-A1 | JAK INHIBITORS AND USES THEREOF | WASHINGTON UNIVERSITY (US) | 2020-09-10 | — | — | US | disclosed |
| EP-2344158-B1 | USE OF ISOQC INHIBITORS | PROBIODRUG AG (DE) | 2017-12-27 | — | — | EP | disclosed |
| WO-2017143014-A1 | JAK INHIBITORS AND USES THEREOF | KIM BRIAN (US) | 2017-08-24 | — | — | WO | disclosed |
| US-9656991-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2017-05-23 | — | — | US | disclosed |
| US-9650362-B2 | Inhibitors | PROBIODRUG AG (DE) | 2017-05-16 | — | — | US | disclosed |
| EP-2865670-B1 | Thiourea derivatives as glutaminyl cyclase inhibitors | PROBIODRUG AG (DE) | 2017-01-11 | — | — | EP | disclosed |
| US-9512082-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2016-12-06 | — | — | US | disclosed |
| US-20080292582-A1 | imidazole derivatives; Alzheimer's Disease, Down syndrome and Huntington's Disease; hypotensive agents; sleeping and eating disorders, anxiolytic agents, antidepressants, antiepileptic agents; drug abuse/withdrawl; 1-(3,4-dimethoxyphenyl)-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea | PROBIODRUG AG (DE) | 2008-11-27 | — | — | US | disclosed |
| US-20080286231-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-11-20 | — | — | US | disclosed |
| US-20080267912-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-10-30 | — | — | US | disclosed |
| WO-2008128983-A1 | CYANO-GUANIDINE DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008128985-A1 | THIOUREA DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008128981-A1 | NITROVINYL-DIAMINE DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008128987-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008128986-A1 | UREA DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2008-10-30 | — | — | WO | disclosed |
| US-20080262063-A1 | Compounds of formula (I), combinations and uses thereof for disease therapy,** Image-1or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein: | PROBIODRUG AG (DE) | 2008-10-23 | — | — | US | disclosed |
| US-20080262065-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASES | PROBIODRUG AG (DE) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080292582-A1 | imidazole derivatives; Alzheimer's Disease, Down syndrome and Huntington's Disease; hypotensive agents; sleeping and eating disorders, anxiolytic agents, antidepressants, antiepileptic agents; drug abuse/withdrawl; 1-(3,4-dimethoxyphenyl)-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea | HTT, MAPT, HYPK | BRD4 670/4885CREBBP 429/4885STAT3 2393/4885 |
| US-20210338812-A1 | JAK1 INHIBITORS AND USES THEREOF | JAK1, JAK2, JAK3 | BRD4 521/4885CREBBP 2112/4885STAT3 16/4885 |
| US-20080262065-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASES | GLS, GLS2, GLUL | BRD4 3146/4885CREBBP 1329/4885STAT3 1320/4885 |
| US-20080286231-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | GLS, GLS2, QPCT | BRD4 2760/4885CREBBP 1314/4885STAT3 1158/4885 |
| US-10973913-B2 | JAK inhibitors and uses thereof | JAK2, JAK1, JAK3 | BRD4 247/4885CREBBP 2845/4885STAT3 14/4885 |
| US-11931412-B2 | JAK1 inhibitors and uses thereof | JAK1, JAK3, JAK2 | BRD4 128/4885CREBBP 1568/4885STAT3 11/4885 |
| US-20080267912-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | GLS, GLS2, QPCT | BRD4 2760/4885CREBBP 1314/4885STAT3 1158/4885 |
| US-20080262063-A1 | Compounds of formula (I), combinations and uses thereof for disease therapy,** Image-1or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein: | MAPT, SLC10A1, REN | BRD4 2519/4885CREBBP 3819/4885STAT3 1465/4885 |
| US-20200282051-A1 | JAK INHIBITORS AND USES THEREOF | JAK2, JAK1, JAK3 | BRD4 247/4885CREBBP 2845/4885STAT3 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.